To Observe the Effect of Isoflurane on the Cognitive Function of the Patient in the Acute Stage of Ischemic Stroke

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030774

Enrollment

Unknown

Registered

2020-03-14

Start date

2021-03-01

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

experimental group:Isoflurane Anesthesia

Contral Group:Local Infiltration Anesthesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to the examination of head imaging and angiography, it is confirmed to meet the relevant diagnostic standards of acute ischemic stroke in the Chinese guide for the diagnosis and treatment of acute ischemic stroke 2019, and digital subtraction angiography is performed to identify the responsible vessels. The patients are accompanied with obvious signs and symptoms of cerebral infarction such as facial numbness, angular deviation, limb numbness, language disorder, consciousness disorder, vertigo, convulsion, etc.; NIHSS Score 10-34; stroke time of anterior circulation < 8h, posterior circulation < 12h; MR diffusion-weighted imaging confirmed cerebral infarction in the blood supply area of cerebral artery; patients were first onset, with complete clinical records.

Exclusion criteria

Exclusion criteria: Early CT Score of Alberta Stroke Programe in patients with anterior and posterior circulation occlusion is less than 6 points; there is bleeding tendency; epilepsy after cerebral infarction; other serious diseases; autoimmune diseases; serious organic dysfunction of liver and kidney; recent (within 2 months) trauma or operation history; diastolic pressure > 110mmhg or systolic pressure > 180mmhg after drug control; serious heart, liver and kidney functions The patients with abnormal or severe mental disorders, expected survival time < 2 years and intracranial venous and venous sinus thrombosis.

Design outcomes

Primary

Measure	Time frame
Montreal cognitive assessment grade (MoCA);NIH stroke scale grade (NIHSS);modified Rankin scales grade (mRS);serum HSP70;serum HIF-1a, HIF-2a;serum NSE;serum TGF-ß1;	—

Secondary

Measure	Time frame
serum caspase-3, caspase-9;serum Bcl-2;	—

Countries

China

Contacts

Public ContactWang Sheng

The First Affiliated Hospital of University of Science And Technology of China

iamsheng2006@163.com+86 18935701573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026